Estrogen Receptor Modulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Estrogen receptor modulators (ERMs) are medications that interact with estrogen receptors in the body. These compounds can either mimic or block the effects of estrogen, thereby modulating hormonal activity in various tissues. ERMs primarily target estrogen receptors, which are present in different organs and tissues throughout the body. These receptors are found in the breast, uterus, bone, and brain, among other locations. ERMs can selectively bind to these receptors, activating or inhibiting their signaling pathways. ERMs exert their effects through different mechanisms. Selective estrogen receptor modulators (SERMs) such as tamoxifen act as estrogen agonists or antagonists, depending on the tissue. For instance, in breast tissue, tamoxifen functions as an antagonist, blocking the estrogen receptor and inhibiting the growth of estrogen-dependent breast cancer cells. In contrast, in bone tissue, SERMs like raloxifene act as agonists, mimicking the effects of estrogen and promoting bone density. ERMs are used in various conditions related to hormonal regulation. Tamoxifen, for instance, is widely used to treat estrogen receptor-positive breast cancer. It helps prevent the growth and recurrence of breast tumors by inhibiting the effects of estrogen. Additionally, raloxifene is utilized in order to avoid and treat osteoporosis in postmenopausal women, as it can enhance bone mineral density. ERMs are also being investigated for their potential benefits in cardiovascular health and as a preventive measure against breast cancer in high-risk individuals. Extensive research is being conducted globally to discover new and novel molecules, like tamoxifen which is used to treat many indications like Breast cancer. The development and launch of new products will thus increase the market's revenue in the forecasted years.

Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have products in their pipelines with 202 products in multiple stages of clinical trials – 2 in Phase 4, 2 in Phase 3, and 2 in Phase 2 of the clinical trials.

Approved Estrogen Receptor Modulator molecules

  • Soltamox (tamoxifen citrate)
  • BR-DIM (oral microencapsulated diindolylmethane)

Drugs in the Pipeline of Estrogen Receptor Modulators

  • Androxal (enclomifene)
  • Estelle (estetrol/drospirenone)
  • fispemifene (HM-101)
  • tamoxifen vaginal (DARE-VVA1)

Clinical Activity and Developments of Estrogen Receptor Modulators

As of July 2023, 9 companies have approximately six products for 128 diseases. For these diseases, 16 trials are being conducted by players globally. For instance,

  • ETOP IBCSG Partners Foundation is conducting a Phase 3 clinical trial to evaluate the role of ovarian function suppression and the role of exemestane as adjuvant therapy for premenopausal women with endocrine-responsive breast cancer that is expected to complete by December 2025.
  • National Cancer Institute is conducting a Phase 3 clinical trial to explore endocrine therapy with or without anti-VEGF therapy for women with hormone receptor-positive advanced breast cancer.
  • National Cancer Institute is conducting a Phase 3 clinical trial to explore Hormone Therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer that is expected to complete by September 2030.

Molecule name

Number of studies

Soltamox (tamoxifen citrate


BR-DIM (oral microencapsulated diindolylmethane)


Androxal (enclomifene)


Estelle (estetrol/drospirenone)


fispemifene (HM-101)


Target Indication Analysis of Estrogen Receptor Modulators

Estrogen receptor modulators (ERMs) have various indications in medicine. They find the most use in treating estrogen receptor-positive breast cancer, where medications like tamoxifen are employed to inhibit the growth and recurrence of breast tumors. ERMs are also utilized in the prevention and treatment of osteoporosis, particularly in postmenopausal women, as they can enhance bone mineral density and reduce the risk of fractures. Furthermore, ERMs such as raloxifene have been found effective in reducing the risk of invasive breast cancer in high-risk individuals. Other indications for ERMs include the management of certain gynecological conditions like endometriosis and uterine fibroids. Additionally, ongoing research is exploring the potential benefits of ERMs in cardiovascular health, cognition, and the prevention of other hormone-related malignancies. The versatile applications of ERMs highlight their significance in multiple areas of medicine, particularly in the fields of oncology and women's health.

Frequently Asked Questions

Soltamox (tamoxifen citrate) and BR-DIM (oral microencapsulated diindolylmethane) are some of the FDA-approved Estrogen Receptor Modulators.

These treat breast cancer, postmenopausal osteoporosis, endometriosis, uterine fibroids, and many more.

AbbVie, Jazz Pharmaceuticals, BioResponse, Mithra Pharmaceuticals, and Mayne Pharma are some of the major market players for Estrogen Receptor Modulators.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of cancers like breast cancer, osteoporosis, uterine fibroids, and more are the key opportunities for Estrogen Receptor Modulators.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • AbbVie
  • Jazz Pharmaceuticals
  • BioResponse
  • Mithra Pharmaceuticals
  • Mayne Pharma
  • Fuji Pharma
  • M3 inc
  • Seelos Therapeutics
  • Daré Bioscience

Adjacent Markets